CY1109264T1 - Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου - Google Patents

Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου

Info

Publication number
CY1109264T1
CY1109264T1 CY20091100828T CY091100828T CY1109264T1 CY 1109264 T1 CY1109264 T1 CY 1109264T1 CY 20091100828 T CY20091100828 T CY 20091100828T CY 091100828 T CY091100828 T CY 091100828T CY 1109264 T1 CY1109264 T1 CY 1109264T1
Authority
CY
Cyprus
Prior art keywords
methods
prevention
treatment
ileus
new methods
Prior art date
Application number
CY20091100828T
Other languages
English (en)
Inventor
John J Farrar
Peter J Schied
William K Schmidt
Randall L Carpenter
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corporation filed Critical Adolor Corporation
Publication of CY1109264T1 publication Critical patent/CY1109264T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Νέες μέθοδοι για την θεραπεία ή/και αποτροπή ειλεού. Οι μέθοδοι μπορεί να περιλαμβάνουν χορήγηση σε έναν ασθενή μιας αποτελεσματικής ποσότητας μιας ένωσης περιφερικού μι ανταγωνιστή οπιούχου. Προτιμώμενες ενώσεις για χρήση στις μεθόδους περιλαμβάνουν πιπεριδινο-Ν-αλκυλκαρβοξυλικά, τεταρτοταγείς μορφινάνες, παράγωγα αλκαλοειδούς του οπίου και τεταρτοταγή βενζομορφάνια. Οι μέθοδοι είναι ιδιαιτέρως κατάλληλες για θεραπεία ή/και αποτροπή μετα-χειρουργικού ειλεού και ειλεού μετά τον τοκετό.
CY20091100828T 1999-11-29 2009-08-05 Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου CY1109264T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45092099A 1999-11-29 1999-11-29
EP00992255A EP1244448B1 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus

Publications (1)

Publication Number Publication Date
CY1109264T1 true CY1109264T1 (el) 2014-07-02

Family

ID=23790061

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100828T CY1109264T1 (el) 1999-11-29 2009-08-05 Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου

Country Status (14)

Country Link
EP (1) EP1244448B1 (el)
JP (2) JP5079961B2 (el)
AT (1) ATE432076T1 (el)
AU (2) AU780738B2 (el)
CA (1) CA2393141C (el)
CY (1) CY1109264T1 (el)
DE (1) DE60042282D1 (el)
DK (1) DK1244448T3 (el)
ES (1) ES2329004T3 (el)
IL (2) IL149650A0 (el)
MX (1) MXPA02005336A (el)
NZ (1) NZ518684A (el)
PT (1) PT1244448E (el)
WO (1) WO2001042207A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP2368554B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2455943C1 (ru) * 2011-02-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ лечения обтурационной формы острой спаечной тонкокишечной непроходимости

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
DE3381877D1 (de) * 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds

Also Published As

Publication number Publication date
CA2393141A1 (en) 2001-06-14
DE60042282D1 (de) 2009-07-09
AU2005203041A1 (en) 2005-08-04
JP5079961B2 (ja) 2012-11-21
WO2001042207A2 (en) 2001-06-14
MXPA02005336A (es) 2003-01-28
CA2393141C (en) 2013-08-13
ES2329004T3 (es) 2009-11-20
NZ518684A (en) 2003-11-28
DK1244448T3 (da) 2009-08-17
PT1244448E (pt) 2009-06-30
JP2003517476A (ja) 2003-05-27
WO2001042207A3 (en) 2002-05-02
AU2005203041B2 (en) 2009-01-08
IL149650A (en) 2011-02-28
EP1244448B1 (en) 2009-05-27
EP1244448A2 (en) 2002-10-02
AU780738B2 (en) 2005-04-14
EP1244448A4 (en) 2003-06-25
JP2012162560A (ja) 2012-08-30
ATE432076T1 (de) 2009-06-15
AU3970501A (en) 2001-06-18
IL149650A0 (en) 2002-11-10
JP5460771B2 (ja) 2014-04-02

Similar Documents

Publication Publication Date Title
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
CA2548834A1 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2001093852A3 (en) Method of treating pain using nalbuphine and opioid antagonists
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
HK1048595A1 (en) Composition for treatment of constipation and irritable bowel syndrome.
WO2004096122A3 (en) Use of ngf antagonists and opioids for treating pain
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
CA2312234A1 (en) Use of methylnaltrexone and related compounds
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
TR199801164T2 (xx) S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri.
EP0915094A4 (en) MORPHINANE DERIVATIVES AND MEDICAL USE THEREOF
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
SE9902267D0 (sv) New compounds
IL120495A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
RU99127690A (ru) Способ лечения опийной наркомании
TH39271A (th) อนุพันธ์สไปโร-ไพเพอริดีน และการใช้งานของสิ่งเหล่านั้นเป็นสารอายุรเวช